Latest On Livzon Pharmaceutical Group Inc (LVZPF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-07-09 06:03 EST | Dividend | A dividend of $1.48 has been announced on Mar 28, 2024. It will be paid Aug 5, 2024 with an ex-dividend date of Jul 9, 2024. | Neutral |  |
| 2023-07-03 06:03 EST | Dividend | A dividend of $1.74 has been announced on Mar 30, 2023. It will be paid Jul 31, 2023 with an ex-dividend date of Jul 3, 2023. | Neutral | |
| 2022-05-31 06:03 EST | Dividend | A dividend of $1.51 has been announced on Mar 28, 2022. It will be paid Jun 24, 2022 with an ex-dividend date of May 31, 2022. | Neutral | |
| 2021-06-02 06:15 EST | Dividend | A dividend of $1.51 has been announced on Mar 22, 2021. It will be paid Jun 25, 2021 with an ex-dividend date of Jun 2, 2021. | Neutral | |
| 2020-11-26 23:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 11:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-27 10:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 17:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 06:04 EST | Dividend | A dividend of $1.25 has been announced on Mar 25, 2020. It will be paid Jun 29, 2020 with an ex-dividend date of Jun 5, 2020. | Neutral | |
| 2020-05-27 07:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 22:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 22:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-11 22:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 23:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 22:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 06:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 00:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 01:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 01:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-14 13:11 EST | Earnings | Earnings have been released on September 30, 2018, with $0.05 earnings per share. | Buy | |
| 2020-02-14 13:11 EST | Earnings | Earnings have been released on June 30, 2018, with $0.05 earnings per share. | Buy | |
| 2020-02-14 13:11 EST | Earnings | Earnings have been released on June 30, 2019, with $0.05 earnings per share. | Buy | |
| 2020-02-14 13:11 EST | Earnings | Earnings have been released on March 31, 2019, with $0.06 earnings per share. | Buy | |
| 2020-02-14 13:11 EST | Earnings | Earnings have been released on December 31, 2018, with $0.02 earnings per share. | Buy | |
| 2020-02-14 13:11 EST | Earnings | Earnings have been released on September 30, 2019, with $0.05 earnings per share. | Buy | |
About Livzon Pharmaceutical Group Inc (LVZPF):
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical products in the People's Republic of China. The company's products include Ilaprazole enteric coated tablets and Laprazole sodium for injection, a series of bismuth potassium citrate granules products, Leuprorelin acetate microspheres for injection, Urofollitropin for injection, Menotropins for injection, Shenqi Fuzheng Injection, anti-viral granules, Voriconazole for Injection, and Mouse nerve growth factor for Injection. It also offers active pharmaceutical ingredients (APIs) and intermediates, such as Mevastatin, Acarbose, Colistin Sulfate, Phenylalanine, and Ceftriaxone Sodium, as well as Pravastatin, Mevastatin, Salinomycin, Vancomycin, etc.; and diagnostic reagents, including ELISA HIV testing reagent, MYCOII testing reagent, and TPPA testing reagent. In addition, the company provides chemical drugs, biochemical drugs, microbiological preparations, and antibiotics; biochemical and polypeptide APIs; chemical APIs, including Cefuroxime Sodium and Cefodizime Sodium; and diagnostic equipment. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.
General
- Name Livzon Pharmaceutical Group Inc
- Symbol LVZPF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 9,019
- Fiscal Year EndDecember
- Web URLhttp://www.livzon.com.cn
View More
Valuation
- Trailing PE 18.7
- Price/Sales (Trailing 12 Mt.) 2.64
- Price/Book (Most Recent Quarter) 2.12
- Enterprise Value Revenue 0.35
- Enterprise Value EBITDA 1.42
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 17%
- Return on Assets 7%
- Return on Equity 17%
- Revenue Per Share $0
- Gross Profit 5.94 billion
- Quarterly Earnings Growth 20.1%
View More
Highlights
- Market Capitalization 4.71 billion
View More
Share Statistics
- Shares Outstanding 319.86 million
- Shares Float 518.51 million
- % Held by Insiders 5107%
- % Held by Institutions 12.36%
View More
Technicals
- Beta 0.6
- 52 Week High $3.7
- 52 Week Low $2.87
- 50 Day Moving Average 3.7
- 200 Day Moving Average 3.7
View More
Dividends
- Forward Annual Dividend Rate $0.17
- Forward Annual Dividend Yield 4.72%
- Payout Ratio 27%
- Dividend Date N/A
- ExDividend Date 2019-07-03
- Dividend Per Share $0.17
- Dividend Yield 0%
View More
Livzon Pharmaceutical Group Inc (LVZPF) Dividend Calendar:
Livzon Pharmaceutical Group Inc pays out 27% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Livzon Pharmaceutical Group Inc (LVZPF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-10-23 | $2.83 billion | $0.44 | $0.41 | 7.32% |
| 2020-06-30 | 2020-09-30 | $2.59 billion | $0.06 | $0.41 | -84.2% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.09 | $0.41 | -77.98% |
| 2019-12-31 | 2020-03-31 | $2.09 billion | $0.06 | $0.24 | -74.71% |
| 2019-09-30 | 2019-12-31 | $2.36 billion | $0.04 | $0.43 | -90.65% |
| 2019-06-30 | 2019-09-30 | $2.33 billion | $0.04 | $0.33 | -86.42% |
| 2019-03-31 | 2019-06-30 | $2.61 billion | $0.05 | $0.37 | -85.43% |
| 2018-12-31 | 2019-03-31 | $2.02 billion | $0.06 | $0.11 | -43.09% |
| 2018-09-30 | 2018-12-31 | $2.28 billion | $0.02 | $0.28 | -92.14% |
| 2018-06-30 | 2018-09-30 | $2.2 billion | $0.05 | $0.26 | -81.54% |
| 2018-03-31 | 2018-06-30 | $2.37 billion | $0.05 | $0.34 | -86.35% |
| 2017-12-31 | 2018-03-31 | $2.01 billion | $0.06 | $0.21 | -71.95% |
| 2017-09-30 | 2017-10-25 | $2.25 billion | $4.02 | $0.28 | 1335.71% |
| 2017-06-30 | 2017-09-30 | $2.15 billion | $0.60 | $0.26 | 132.12% |
| 2017-03-31 | 2017-06-30 | $0.04 | $0.34 | -89.62% | |
| 2016-12-31 | 2017-03-31 | $0.04 | $0.19 | -77.37% | |
| 2016-09-30 | 2016-12-31 | $0.03 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | $0.04 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.03 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.04 | $0.28 | -85.14% | |
| 2015-09-30 | 2015-12-31 | $0.02 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.03 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.03 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.04 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.02 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.03 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.03 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.03 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.02 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.02 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.02 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.03 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.02 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.02 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.02 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.02 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.02 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.01 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.02 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.02 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.02 | $0.00 |
Livzon Pharmaceutical Group Inc (LVZPF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | 277.81 million | 172.55 million | N/A | 250.82 million | 193.61 million |
| Income Before Tax | 584.03 million | 1.01 billion | N/A | 326.96 million | 412.63 million |
| Selling General Administrative | 1.06 billion | 602.17 million | N/A | 763.63 million | 906.88 million |
| Gross Profit | 1.88 billion | 1.74 billion | N/A | 1.27 billion | 1.52 billion |
| Ebit | 592.02 million | 1.04 billion | N/A | 181.63 million | 404.4 million |
| Operating Income | 578.56 million | 840.91 million | N/A | 336.56 million | 404.4 million |
| Income Tax Expense | 88.35 million | 144.41 million | 82.51 million | 40.29 million | 72.25 million |
| Total Revenue | 2.83 billion | 2.59 billion | N/A | 2.09 billion | 2.36 billion |
| Cost of Revenue | 949.37 million | 853.7 million | N/A | 816.5 million | 840.65 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 8.23 million |
| Net Income From Continuing Operations | 495.69 million | 868.11 million | N/A | 286.68 million | 340.38 million |
| Net Income Applicable to Common Shares | 416.8 million | 605.38 million | 399.36 million | 263.04 million | 300.89 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | 27.59 million | N/A | -37.13 million | -41.53 million |
| Change to Liabilities | -23.43 million | 23.43 million | N/A | -7.69 million | -151.87 million |
| Total Cash Flow from Investing Activities | -196.08 million | 27.59 million | -134.53 million | -37.13 million | -149.46 million |
| Net Borrowings | 1.2 billion | -4.7 million | -1.08 billion | 1.36 billion | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | -894.16 million |
| Change to Operating Activities | -12.64 million | 12.64 million | N/A | 15.61 million | N/A |
| Change in Cash | N/A | -720.23 million | N/A | 1.64 billion | -546.94 million |
| Total Cash from Operating Activities | 644.3 million | 510.73 million | 362.85 million | 338.94 million | 469.86 million |
| Depreciation | N/A | N/A | N/A | N/A | -180.89 million |
| Other Cash Flow from Investing Activities | 11.34 million | 16.85 million | 14.14 million | 54.31 million | -8.22 million |
| Change to Inventory | N/A | N/A | N/A | N/A | -67.77 million |
| Change to Account Receivables | N/A | N/A | N/A | N/A | 325.57 million |
| Other Cash Flow from Financing Activities | -237.79 million | -320.29 million | 25528 | -12.77 million | -26.21 million |
| Change to Net Income | -148.06 million | -45.08 million | -36.51 million | -158.08 million | 254.49 million |
| Capital Expenditures | N/A | 118.44 million | N/A | 105.16 million | 100.06 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 6.2 billion | 4.72 billion | N/A | 5.7 billion | 4.39 billion |
| Total Stockholder Equity | 11.6 billion | 11.1 billion | N/A | 11.17 billion | 10.86 billion |
| Other Current Liabilities | 2.54 billion | 110.63 million | N/A | 151.77 million | 2.61 billion |
| Total Assets | 19.32 billion | 17.25 billion | N/A | 17.98 billion | 16.33 billion |
| Common Stock | 943.59 million | 940.77 million | 935.66 million | 934.76 million | 934.76 million |
| Other Current Assets | 125.35 million | 130.21 million | N/A | 128.28 million | 314.8 million |
| Retained Earnings | 8.77 billion | 8.35 billion | 9.44 billion | 8.42 billion | 8.78 billion |
| Other Liabilities | 405.65 million | 414.59 million | 402.66 million | 407.57 million | 330.82 million |
| Other Assets | 780.89 million | 754.44 million | 722.73 million | 725.84 million | 670.29 million |
| Cash | 9.04 billion | 7.28 billion | N/A | 8.86 billion | 7.22 billion |
| Total Current Liabilities | 5.8 billion | 4.3 billion | N/A | 5.29 billion | 4.06 billion |
| Other Stockholder Equity | 1.51 billion | 51.75 million | 33.11 million | 98.69 million | -7.62 million |
| Property, Plant & Equipment | 3.61 billion | 3.52 billion | 3.44 billion | 3.39 billion | 3.42 billion |
| Total Current Assets | 13.85 billion | 11.92 billion | N/A | 12.87 billion | 11.3 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 609.21 million |
| Net Tangible Assets | 11.26 billion | 10.76 billion | 11.28 billion | 10.83 billion | 10.53 billion |
| Short Term Investments | 22.24 million | 13.91 million | N/A | 17.19 million | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 1.38 billion | 1.43 billion | N/A | 1.17 billion | 1.09 billion |
| Accounts Payable | 1.47 billion | 1.35 billion | N/A | 1.26 billion | 1.27 billion |
Livzon Pharmaceutical Group Inc (LVZPF) Chart:
Livzon Pharmaceutical Group Inc (LVZPF) News:
Below you will find a list of latest news for Livzon Pharmaceutical Group Inc (LVZPF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Livzon Pharmaceutical Group Inc (LVZPF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Livzon Pharmaceutical Group Inc (LVZPF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|